MUCOPOLYSACCHARIDOSES

33

Mucopolysaccharidoses (MPS) represent a group of rare, inherited metabolic disorders that impact the body’s ability to break down glycosaminoglycans (GAGs). These complex sugar molecules are essential for building bone, cartilage, skin, tendons, and other tissues. When the body cannot break them down properly, GAGs accumulate in cells, blood, and connective tissues, leading to progressive damage.

Causes and types of Mucopolysaccharidoses

Mucopolysaccharidoses are caused by mutations in specific genes responsible for producing enzymes that break down GAGs. Each type of MPS corresponds to a deficiency or malfunction of a different enzyme:

• MPS I (Hurler, Hurler-Scheie, and Scheie syndromes): Deficiency in the enzyme alpha-L-iduronidase.
• MPS II (Hunter syndrome): Deficiency in iduronate-2-sulfatase.
• MPS III (Sanfilippo syndrome): Deficiencies in enzymes like heparan N-sulfatase, alpha-N-acetylglucosaminidase, among others.
• MPS IV (Morquio syndrome): Deficiencies in enzymes such as N-acetylgalactosamine-6-sulfatase or beta-galactosidase.
• MPS VI (Maroteaux-Lamy syndrome): Deficiency in arylsulfatase B.
• MPS VII (Sly syndrome): Deficiency in beta-glucuronidase.

These genetic mutations are usually inherited in an autosomal recessive pattern, meaning both parents must carry and pass on the defective gene.

Prevalence

Mucopolysaccharidoses are rare, with an estimated incidence of 1 in 25,000 births. However, the prevalence of each type varies:

• MPS I: Approximately 1 in 100,000 live births.
• MPS II: Around 1 in 100,000 to 1 in 170,000 live births, predominantly affecting males.
• MPS III: Roughly 1 in 70,000 births.
• MPS IV: About 1 in 200,000 to 1 in 300,000 live births.
• MPS VI: Close to 1 in 250,000 live births.
• MPS VII: Extremely rare, with fewer than 100 cases reported worldwide.

Symptoms

Symptoms of MPS vary widely depending on the type and severity but often include:

• Developmental delays and cognitive impairment.
• Coarse facial features.
• Enlarged liver and spleen (hepatosplenomegaly).
• Skeletal abnormalities such as short stature and joint stiffness.
• Hearing loss and vision problems.
• Heart valve abnormalities.
• Respiratory issues.

Risk Factors

The primary risk factor for MPS is having parents who carry the mutated gene. Consanguineous marriages (marriages between close relatives) increase the likelihood of inheriting these conditions.

Diagnosis

Diagnosing MPS involves several steps:

1. Clinical Evaluation: Initial assessment based on physical symptoms and family history.
2. Urine Test: Detects excessive amounts of GAGs.
3. Enzyme Assay: Measures the activity of specific enzymes in blood, skin cells, or other tissues.
4. Genetic Testing: Confirms the diagnosis by identifying mutations in the relevant genes.

Treatments

While there is no cure for MPS, various treatments can manage symptoms and improve quality of life:

• Enzyme Replacement Therapy (ERT): Provides the deficient enzyme through regular infusions.
• Hematopoietic Stem Cell Transplantation (HSCT): Replaces the defective cells with healthy ones from a donor.
• Surgery: Corrects physical deformities and addresses complications like heart or joint issues.
• Medications: Alleviate specific symptoms such as pain or respiratory problems.

Home Care Tips

Managing MPS at home involves:

• Regular Monitoring: Keep track of the patient’s health and report any changes to healthcare providers.
• Physical Therapy: Helps maintain mobility and reduce joint stiffness.
• Occupational Therapy: Assists with daily activities and enhances quality of life.
• Nutritional Support: Ensures a balanced diet to meet the patient’s specific needs.
• Support Groups: Connect with others who understand the challenges of MPS.

Prevention

Currently, there is no way to prevent MPS due to its genetic nature. However, genetic counseling can help prospective parents understand their risk and make informed decisions.

When to See a Doctor

Seek medical advice if your child shows signs of developmental delays, unusual physical features, or other symptoms associated with MPS. Early diagnosis and intervention are crucial for managing the condition effectively.

Outlook/Prognosis

The prognosis for individuals with MPS varies widely. Some may live relatively normal lives with appropriate treatment, while others may experience severe complications that shorten their lifespan. Continuous advancements in medical research and therapies offer hope for improved outcomes and quality of life for those affected by MPS.

Sources

1. National Organization for Rare Disorders (NORD)
2. National Institutes of Health (NIH)
3. Mayo Clinic
4. Genetics Home Reference
5. Orphanet: The Portal for Rare Diseases and Orphan Drugs